233 related articles for article (PubMed ID: 33330386)
21. Specificity of the SH2 domains of SHP-1 in the interaction with the immunoreceptor tyrosine-based inhibitory motif-bearing receptor gp49B.
Wang LL; Blasioli J; Plas DR; Thomas ML; Yokoyama WM
J Immunol; 1999 Feb; 162(3):1318-23. PubMed ID: 9973385
[TBL] [Abstract][Full Text] [Related]
22. Effects of Src homology domain 2 (SH2)-containing inositol phosphatase (SHIP), SH2-containing phosphotyrosine phosphatase (SHP)-1, and SHP-2 SH2 decoy proteins on Fc gamma RIIB1-effector interactions and inhibitory functions.
Nakamura K; Brauweiler A; Cambier JC
J Immunol; 2000 Jan; 164(2):631-8. PubMed ID: 10623804
[TBL] [Abstract][Full Text] [Related]
23. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
24. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies.
Song Z; Wang M; Ge Y; Chen XP; Xu Z; Sun Y; Xiong XF
Acta Pharm Sin B; 2021 Jan; 11(1):13-29. PubMed ID: 33532178
[TBL] [Abstract][Full Text] [Related]
25. Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain-containing protein tyrosine phosphatase (SHP2) inhibitor at molecular level through molecular docking and molecular dynamics.
Wang RR; Liu WS; Zhou L; Ma Y; Wang RL
J Biomol Struct Dyn; 2020 Mar; 38(5):1525-1538. PubMed ID: 31043123
[TBL] [Abstract][Full Text] [Related]
26. T cell-specific constitutive active SHP2 enhances T cell memory formation and reduces T cell activation.
Cammann C; Israel N; Frentzel S; Jeron A; Topfstedt E; Schüler T; Simeoni L; Zenker M; Fehling HJ; Schraven B; Bruder D; Seifert U
Front Immunol; 2022; 13():958616. PubMed ID: 35983034
[TBL] [Abstract][Full Text] [Related]
27. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.
Chemnitz JM; Parry RV; Nichols KE; June CH; Riley JL
J Immunol; 2004 Jul; 173(2):945-54. PubMed ID: 15240681
[TBL] [Abstract][Full Text] [Related]
28. SH2 domain-containing inositol polyphosphate 5'-phosphatase is the main mediator of the inhibitory action of the mast cell function-associated antigen.
Xu R; Abramson J; Fridkin M; Pecht I
J Immunol; 2001 Dec; 167(11):6394-402. PubMed ID: 11714805
[TBL] [Abstract][Full Text] [Related]
29. Intramolecular Interaction with the E6 Region Stabilizes the Closed Conformation of the N-SH2 Domain and Concurs with the Self-Inhibitory Docking in Downregulating the Activity of the SHP2 Tyrosine Phosphatase: A Molecular Dynamics Study.
Bellacchio E
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563185
[TBL] [Abstract][Full Text] [Related]
30. Immunoreceptor tyrosine-based inhibitory motif of the IL-4 receptor associates with SH2-containing phosphatases and regulates IL-4-induced proliferation.
Kashiwada M; Giallourakis CC; Pan PY; Rothman PB
J Immunol; 2001 Dec; 167(11):6382-7. PubMed ID: 11714803
[TBL] [Abstract][Full Text] [Related]
31. Phosphopeptide binding to the N-SH2 domain of tyrosine phosphatase SHP2 correlates with the unzipping of its central β-sheet.
Marasco M; Kirkpatrick J; Carlomagno T; Hub JS; Anselmi M
Comput Struct Biotechnol J; 2024 Dec; 23():1169-1180. PubMed ID: 38510972
[TBL] [Abstract][Full Text] [Related]
32. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
33. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
[TBL] [Abstract][Full Text] [Related]
34. Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2
Zhou L; Feng Y; Ma YC; Zhang Z; Wu JW; Du S; Li WY; Lu XH; Ma Y; Wang RL
J Mol Graph Model; 2021 Mar; 103():107807. PubMed ID: 33338846
[TBL] [Abstract][Full Text] [Related]
35. Structural and functional dissection of the cytoplasmic domain of the transmembrane adaptor protein SIT (SHP2-interacting transmembrane adaptor protein).
Pfrepper KI; Marie-Cardine A; Simeoni L; Kuramitsu Y; Leo A; Spicka J; Hilgert I; Scherer J; Schraven B
Eur J Immunol; 2001 Jun; 31(6):1825-36. PubMed ID: 11433379
[TBL] [Abstract][Full Text] [Related]
36. Differential Mechanisms for SHP2 Binding and Activation Are Exploited by Geographically Distinct Helicobacter pylori CagA Oncoproteins.
Hayashi T; Senda M; Suzuki N; Nishikawa H; Ben C; Tang C; Nagase L; Inoue K; Senda T; Hatakeyama M
Cell Rep; 2017 Sep; 20(12):2876-2890. PubMed ID: 28930683
[TBL] [Abstract][Full Text] [Related]
37. Fc gamma receptor type IIb induced recruitment of inositol and protein phosphatases to the signal transductory complex of human B-cell.
Sarmay G; Koncz G; Pecht I; Gergely J
Immunol Lett; 1997 Jun; 57(1-3):159-64. PubMed ID: 9232445
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of Folding and Binding of the N-Terminal SH2 Domain from SHP2.
Bonetti D; Troilo F; Toto A; Travaglini-Allocatelli C; Brunori M; Gianni S
J Phys Chem B; 2018 Dec; 122(49):11108-11114. PubMed ID: 30047735
[TBL] [Abstract][Full Text] [Related]
39. Co-clustering of Fcgamma and B cell receptors induces dephosphorylation of the Grb2-associated binder 1 docking protein.
Koncz G; Tóth GK; Bökönyi G; Kéri G; Pecht I; Medgyesi D; Gergely J; Sármay G
Eur J Biochem; 2001 Jul; 268(14):3898-906. PubMed ID: 11453982
[TBL] [Abstract][Full Text] [Related]
40. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.
Tang K; Jia YN; Yu B; Liu HM
Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
